Empagliflozin as a novel therapy for cirrhotic refractory ascites: a randomized controlled study

Autor:	Mohamed Fathy Bakosh, Ramy Mohamed Ghazy, Walid Ismail Ellakany, Ahmed Kamal
Jazyk:	angličtina
Rok vydání:	2024
Předmět:	Ascites Sodium-glucose transporter 2 inhibitors Empagliflozin Diuretics Natriuretic agents Surgery RD1-811 Diseases of the digestive system. Gastroenterology RC799-869
Zdroj:	Egyptian Liver Journal, Vol 14, Iss 1, Pp 1-10 (2024)
Druh dokumentu:	article
ISSN:	2090-6226
DOI:	10.1186/s43066-024-00383-y
Popis:	Abstract Background Cirrhotic refractory ascites (RA) patients have few alternatives for treatment. Empagliflozin is now known to have natriuretic and neurohormonal modulatory effects. This research investigated the safety and efficacy of empagliflozin in the management of RA when added to the standard of care (SoC) compared to SoC alone. Methods Patients were randomized to receive either a fixed dose of 10 mg of empagliflozin plus standard of care (SoC) or SoC alone. Patients were followed up for 3 months. The primary endpoint was achieving no need for large-volume paracentesis (LVP). Results Forty-two patients were randomized equally, and intention-to-treat was performed. There was a statistically significant decrease in the need for LVP in the empagliflozin group compared to the SoC group (100% in the SoC vs. 42.9% in the empagliflozin group, p
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/15a50bbcfa6c412f8aedc5696734d9f5 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.